miR-497 expression, function and clinical application in cancer

Gang Yang; Guangbing Xiong; Zhe Cao; Suli Zheng; Lei You; Taiping Zhang; Yupei Zhao

doi:10.18632/oncotarget.10152

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

miR-497 expression, function and clinical application in cancer

Gang Yang, Guangbing Xiong, Zhe Cao, Suli Zheng, Lei You, Taiping Zhang and Yupei Zhao _

PDF | HTML | How to cite

Oncotarget. 2016; 7:55900-55911. https://doi.org/10.18632/oncotarget.10152

Metrics: PDF 2199 views | HTML 3258 views | ?

Abstract

Gang Yang1,*, Guangbing Xiong1,*, Zhe Cao1,*, Suli Zheng1, Lei You1, Taiping Zhang1 and Yupei Zhao1

1 Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

* These authors contributed equally to this work

Correspondence to:

Taiping Zhang, email:

Yupei Zhao, email:

Keywords: miR-497; carcinogenesis; biomarker; clinical application

Received: April 01, 2016 Accepted: June 06, 2016 Published: June 17, 2016

Abstract

MicroRNAs (miRNAs) are small non-coding RNAs that inhibit gene expression by binding to the 3’ untranslated region (3’-UTR) of their target mRNAs. Recent studies show that miR-497 plays an important role in various cancers. Here, we summarize the existing studies of miR-497 as following: (1) miR-497 expression in cancer; (2) regulation mechanisms of miR-497 expression; (3) function of miR-497 in cancer; (4) direct targets of miR-497; (5) Clinical applications of miR-497. Recent analyses verify that miR-497 mainly suppresses tumors; however, it also acts as an oncogene in several cancers. Increasing evidence indicates that miR-497 can serve as a diagnostic and prognostic biomarker and is a promising therapeutic target for future clinical applications.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10152

Publication Alerts

Reviews:

miR-497 expression, function and clinical application in cancer

Abstract